Distinct α subunit variations of the hypothalamic GABAA receptor triplets (αβγ) are linked to hibernating state in hamsters.
BACKGROUND
The structural arrangement of the γ-aminobutyric acid type A receptor (GABAAR) is known to be crucial for the maintenance of cerebral-dependent homeostatic mechanisms during the promotion of highly adaptive neurophysiological events of the permissive hibernating rodent, i.e the Syrian golden hamster. In this study, in vitro quantitative autoradiography and in situ hybridization were assessed in major hypothalamic nuclei. Reverse Transcription Reaction-Polymerase chain reaction (RT-PCR) tests were performed for specific GABAAR receptor subunit gene primers synthases of non-hibernating (NHIB) and hibernating (HIB) hamsters. Attempts were made to identify the type of αβγ subunit combinations operating during the switching ON/OFF of neuronal activities in some hypothalamic nuclei of hibernators.


RESULTS
Both autoradiography and molecular analysis supplied distinct expression patterns of all α subunits considered as shown by a strong (p < 0.01) prevalence of α1 ratio (over total α subunits considered in the present study) in the medial preoptic area (MPOA) and arcuate nucleus (Arc) of NHIBs with respect to HIBs. At the same time α2 subunit levels proved to be typical of periventricular nucleus (Pe) and Arc of HIB, while strong α4 expression levels were detected during awakening state in the key circadian hypothalamic station, i.e. the suprachiasmatic nucleus (Sch; 60%). Regarding the other two subunits (β and γ), elevated β3 and γ3 mRNAs levels mostly characterized MPOA of HIBs, while prevalently elevated expression concentrations of the same subunits were also typical of Sch, even though this time during the awakening state. In the case of Arc, notably elevated levels were obtained for β3 and γ2 during hibernating conditions.


CONCLUSIONS
We conclude that different αβγ subunits are operating as major elements either at the onset of torpor or during induction of the arousal state in the Syrian golden hamster. The identification of a brain regional distribution pattern of distinct GABAAR subunit combinations may prove to be very useful for highlighting GABAergic mechanisms functioning at least during the different physiological states of hibernators and this may have interesting therapeutic bearings on neurological sleeping disorders.
Alò
Raffaella
R
Comparative Neuroanatomy Laboratory, Ecology Department, University of Calabria, Ponte Pietro Bucci, 87030 Arcavacata di Rende, Cosenza, Italy. canonaco@unical.it
Avolio
Ennio
E
Di Vito
Anna
A
Carelli
Antonio
A
Facciolo
Rosa Maria
RM
Canonaco
Marcello
M
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000378:metabolism; D001345:Autoradiography; D001667:Binding, Competitive; D006224:Cricetinae; D017931:DNA Primers; D005260:Female; D005442:Flumazenil / Q000378:metabolism; D018757:GABA Modulators / Q000378:metabolism; D006605:Hibernation / Q000235:genetics / Q000502:physiology*; D007031:Hypothalamus / Q000378:metabolism*; D017403:In Situ Hybridization; D008647:Mesocricetus; D011301:Preoptic Area / Q000378:metabolism; D018079:Receptors, GABA / Q000235:genetics / Q000378:metabolism; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013493:Suprachiasmatic Nucleus / Q000378:metabolism
D017931:DNA Primers; D018757:GABA Modulators; D018079:Receptors, GABA; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D005442:Flumazenil
Pharmacol Rev. 1998 Jun;50(2):291-313
9647870
J Neurochem. 1994 Feb;62(2):815-8
7507518
Hippocampus. 2009 Nov;19(11):1103-14
19338020
Metabolism. 2006 Oct;55(10 Suppl 2):S30-5
16979424
Nat Rev Neurosci. 2001 Apr;2(4):240-50
11283747
Physiol Genomics. 2002 Aug 14;10(2):93-102
12181366
Hum Genet. 2002 Aug;111(2):154-60
12189488
J Neurosci. 2007 Aug 1;27(31):8184-9
17670965
Indian J Physiol Pharmacol. 2002 Oct;46(4):434-40
12683218
Exp Brain Res. 2002 Feb;142(4):504-11
11845246
Brain Res Mol Brain Res. 2002 Jul 15;104(1):47-54
12117550
Neuropharmacology. 2009 Sep;57(4):446-55
19555700
Exp Brain Res. 2000 Feb;130(3):309-19
10706430
Am J Pathol. 2001 Jun;158(6):2145-51
11395392
Pharmacol Ther. 2006 Dec;112(3):612-29
16876255
J Neuroendocrinol. 2005 May;17(5):269-75
15869561
Neuropharmacology. 2009 Jan;56(1):141-8
18760291
Neuroscience. 2002;111(2):231-9
11983310
J Appl Physiol (1985). 2002 Jun;92(6):2640-7
12015384
Neuropharmacology. 2002 Nov;43(6):925-37
12423662
Am J Physiol Regul Integr Comp Physiol. 2009 May;296(5):R1606-12
19244580
J Neurosci. 2005 Dec 7;25(49):11219-30
16339017
Trends Neurosci. 1996 Apr;19(4):139-43
8658597
Pharmacol Ther. 2003 Jun;98(3):299-323
12782242
Lancet. 2003 Sep 27;362(9389):1028-37
14522533
J Neurosci. 1999 May 15;19(10):3781-90
10234010
Neurochem Int. 1999 May;34(5):379-85
10397365
Nature. 2009 Oct 22;461(7267):1122-5
19847264
Brain Res. 1997 Sep 5;767(2):361-2
9367269
Trends Neurosci. 2007 Jul;30(7):343-9
17532059
J Neurochem. 2007 Jul;102(1):1-12
17394533
Environ Health Perspect. 2002 Jun;110 Suppl 3:397-402
12060835
Ann N Y Acad Sci. 1999 Apr 30;868:645-53
10414349
J Neurosci. 2006 Nov 1;26(44):11342-6
17079662
Neuropharmacology. 2002 Sep;43(4):482-91
12367595
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12156-61
19584253
J Neurosci. 2004 Feb 25;24(8):1812-21
14985421
J Neuroendocrinol. 2004 Jul;16(7):589-604
15214862
Front Mol Neurosci. 2008 Mar 28;1:5
18946538
Indian J Physiol Pharmacol. 2001 Oct;45(4):445-50
11883151
Pharmacol Ther. 2004 Jun;102(3):195-221
15246246
Pharmacol Biochem Behav. 2008 Jul;90(1):105-12
18201756
Chronobiol Int. 2000 Mar;17(2):103-28
10757457
Science. 2004 Mar 12;303(5664):1681-3
15017002
J Neurophysiol. 2003 Jan;89(1):128-34
12522165
Brain Res. 1999 Oct 23;845(2):215-23
10536201
J Neurochem. 2007 Sep;102(6):1713-1726
17555547
Science. 2006 Mar 17;311(5767):1595-9
16543457
BMC Neurosci. 2007 Oct 10;8:85
17927825
Anal Biochem. 1987 Apr;162(1):156-9
2440339